This manuscript presents a step-by-step protocol for screening compounds at gamma-aminobutyric acid type A (GABA A ) receptors and its use towards the identification of novel molecules active in preclinical assays from an in vitro recombinant receptor to their pharmacological effects at native receptors in rodent brain slices. For compounds binding at the benzodiazepine site of the receptor, the first step is to set up a primary screen that consists of developing radioligand binding assays on cell membranes expressing the major GABA A subtypes. Then, taking advantage of the heterologous expression of rodent and human GABA A receptors in Xenopus oocytes or HEK 293 cells, it is possible to explore, in electrophysiological assays, the physiological properties of the different receptor subtypes and the pharmacological properties of the identified compounds. The Xenopus oocyte system will be presented here, starting with the isolation of the oocytes and their microinjection with different mRNAs, up to the pharmacological characterization using two-electrode voltage clamps. Finally, recordings conducted in rodent brain slices will be described that are used as a secondary physiological test to assess the activity of molecules at their native receptors in a well-defined neuronal circuit. Extracellular recordings using population responses of multiple neurons are demonstrated together with the drug application.
Introduction
Here, we present protocols for the discovery of compounds active at GABA A receptors, from the binding to the physiology and pharmacology. In the search for novel molecules specific for GABA A receptors, it is crucial to define, as precisely as possible, the subtype of interest and the assessment of the specificity of the newly identified compounds (e.g., for a review, see Rudolph Binding assays have been and are still largely used as the first step in drug discovery. In the case of GABA A receptors, they are optimized to identify compounds that bind to the benzodiazepine binding site of the receptor where therapeutically useful and safe drugs bind. Other techniques, using fluorometric imaging plate reader (FLIPR) membrane potential red dye-based assays 3 , detect compounds like barbiturates that bind to additional sites that are less desirable due to their unwanted side-effect profile. In addition, the utilized dyes can directly activate GABA A receptors, thus questioning the utility of these assays for drug discovery 4 . Binding assays can only provide the evidence that a given compound can bind to a specific receptor class. In vitro assays with cell membranes are used to identify selective human GABA A α5β3γ2 receptor ligands. Transiently transfected HEK293 cells expressing the human GABA A α5β3γ2, α1β3γ2, α2β3γ2, and α3β3γ2 receptors are used to prepare membranes for these assays. The effect of the ligands is detected by measuring the scintillation of [ X = the log 10 of the concentration of the competing compound, D = the slope of the curve (a Hill coefficient). 3. Calculate the binding affinity (Ki) using the half maximal inhibitory concentration (IC 50 ) and incubate them in 50 mL of OR2 medium without CaCl 2 (OR2-noCaCl 2 ) containing 0.2% collagenase (Type I) at 17-19 °C in a 100 mL spinner flask with a slow agitation for 4-5 h. Verify that the magnetic bar is placed approximately 3-5 cm above the bottom of the spinner flask to avoid crushing the oocytes. 7. After 4-5 h, verify that most of the oocytes are freed from their follicle (i.e., they swim around individually). Wash them 5x with 200 mL of OR2 supplemented with 1.8 mM CaCl 2 . 8. Transfer the defolliculated oocytes to Petri-dishes (10 cm) filled with Barth solution and antibiotics/antimycotics and keep them at least overnight at 17 °C before the cDNA or mRNA injection. 9. On the next day, select, under a binocular, a healthy oocyte presenting a clear and distinct animal versus a vegetal pole (dark brown for the animal pole versus light yellow for the vegetal pole). Use clean Pasteur pipettes and dispose the oocytes one by one into a sterile conical 96-injection well plate. NOTE: No special care is needed in the placement of the oocytes for the mRNA injections; whereas, for the cDNA injections, it is indispensable to orient the oocytes with the animal pole facing upward.
2. mRNA or cDNA automatic injection 1. Synthesize the mRNAs using a commercially available kit following the recommended instructions. Clean the instruments and the table with RNase and wear the appropriate protecting gloves. NOTE: The quality of the mRNA is determinant to yield a good expression, and it is indispensable to prevent mRNA degradation during the injection procedure. 2. Prepare cDNAs using a commercially available kit and dissolve the desired amount in bidistilled water at a concentration of 0.2 µg/µL. 3. Inject 10-50 nL of mRNA solution at a concentration of 0.2 µg/µL, or 10 nL of cDNA solution at a concentration ranging from 0.02-0.2 µg/µL, preferably in batches of 95 oocytes. 4. For membrane proteins requiring multiple subunits (i.e., heteromeric α1β2γ2 GABA A receptors), mix the corresponding mRNAs or cDNAs in the desired ratio (i.e., 1:1:1 or 1:10:1). 5. Keep the oocyte at 17 °C to prevent the expression of heat shock proteins by the oocytes; store the microplate in a thermo-controlled storage area. 6. Dissolve the test compounds which were tested positive in the binding assay in OR2 at 0.1-1,000 µM for electrophysiological recordings and dispose them off in a 96-well flat bottom polypropylene plate.
3. Plasmids for expression 1. Follow the instruction manuals of commercially available kits for the mRNA synthesis with bacterial T7 or T6 promotors and make 20 µL of a solution at 0.2 µg/µL in RNase-free water. 2. Prepare at least 20 µL of a solution containing a eukaryote expression vector for the cDNA expression, typically at 0.2 µg/µL dissolved in bidistilled water.
4. Microinjection in the Oocyte and Visualization of its Quality 1. Inject 10-50 nL of the solution containing plasmid (see step 2.3.1 or 2.3.2) using a glass micro-injection needle with a tip diameter ranging up to 100 µm mounted on a micromanipulator equipped with a pressure ejection system or with an automated injection system. NOTE: In the example discussed here, oocytes are injected by batches of 95 with an automated system suitable for use with cDNA or mRNA. 2. Fill the injection needle with 1 µL of a dye such as methylene blue at 1% and inject the oocytes using the standard procedure (either in the nucleus for cDNA or in the cytoplasm for mRNA). 3. Dispose the injected oocytes for about 1 min in boiling water. Cut the oocytes in half with a razor blade under a binocular.
NOTE: The dye remains localized as shown in Figure 3E , allowing a precise observation of the injection.
5. Two-electrode voltage clamp recordings 1. Place the well plate containing the oocytes on the automated system, which uses the principle illustrated in Figure 4 . NOTE: In contrast to the patch clamp system illustrated in Figure 5 , the true membrane potential of the cell is read by the voltage electrode.
Copyright Program the automated recording system using the icon-based interface with, for example, the scheme illustrated in Figure 6 for the determination of the concentration activity relationship.
6. Curve fitting 1. Analyze the results using the appropriate software, using the illustrated concentration activation curve, plot the current amplitude as a function of the logarithm of the agonist concentration. 2. Observe the sigmoidal curve that can be subsequently fitted with the empirical Hill equation in the form:
Here, Y= the fraction of evoked current, EC 50 = the concentration for a 50% activation, x = the concentration of the compound, n H = the Hill coefficient or apparent cooperativity. 3. Normalize the currents to a unity by dividing the amplitude of each response versus the value recorded at the highest concentration to analyze the data obtained from a series of cells. 4. Determine the average and standard errors and realize the curve fitting using standardly available software.
Electrophysiological Recordings in Brain Slices
NOTE: Hippocampal rat slices are prepared in accordance with the national and institutional guidelines.
Preparation of hippocampus slices
1. Prepare the dissection artificial cerebro-spinal fluid (dACSF) with 124 mM NaCl 124, 2. 3 , and 10 mM glucose gassed in the bottle with a mixture of 95% O 2 and 5% CO 2 . 3. Anesthetize the rats using a mixture of 2.5% isoflurane and pure oxygen and decapitate them. 4. Cut the scalp following the midline with a fine pair of scissors. Cut the skull along the midline without damaging the underlying tissue.
Remove the skull with tweezers and use a fine spatula to scoop out the brain. 5. Place the brain in the gassed dACSF solution at RT and dissect the left hippocampal formation with a fine spatula. 6. Cut transverse slices (400 µm thick) from the medium part of the hippocampus with a tissue chopper and transfer them to the recording chamber with the use of a painting brush. Maintain the slices at RT for 45 min. 7. Perfuse the slices with the gassed rACSF at 35 °C and at a rate of 1.5 mL/min. Bubble the solution with a mixture of 95% O 2 and 5% CO 2 . NOTE: After this step, the slices are ready for the electrophysiological experiments.
2. Single population spike recording 1. Place a brain slice into the microscope-mounted chamber. 2. Perfuse the slice at a rate of 3 mL/min with rACSF. 3. Pull a borosilicate glass micropipette with the pipette puller having a resistance of ~2 MΩ. NOTE: This micropipette is used as a recording electrode and is electrically connected to the amplifier. 4. Fill the micropipette with a solution containing 2 M NaCl and place it into the pipette holder of the amplifier. 5. Position the recording micropipette in the stratum pyramidale in the CA1 region of the hippocampal slice using the right micromanipulator. NOTE: The location is schematically represented in Figure 7 . 6. Place an insulated bipolar platinum/iridium electrode into the holder on the left micromanipulator.
NOTE: This electrode is used as the stimulation electrode and is electrically connected to the stimulus generator. 7. Position the stimulation electrode in the Schaffer collaterals in the CA1 region of the hippocampal slice using the right micromanipulator. NOTE: The location is schematically represented in Figure 7 . 8. Deliver a current pulse to the stimulation electrode using the stimulus generator every 30 s (100 µs durations, starting at 10 µA) and gradually increase the stimulation strength until a population spike (PS) appears. 9. Adjust the stimulus strength to evoke a PS corresponding to 45% of the maximum amplitude that can be obtained. PSs are filtered at 2.4 KHz and digitized at 20 KHz using the signal amplifier.
3. Paired-pulse inhibition 1. Prepare the brain slices (step 3.1) and proceed as described previously (steps 3.2.1-3.2.7).
2. Deliver two current pulses (100 µs durations at a 20 ms interval) to the stimulation electrode every 30 s using the stimulus generator. Set the stimulus strength to evoke a PS corresponding to 45% of the maximum amplitude.
4. Compound testing 1. Make dilutions of the compounds to be tested in gassed ACSF so that the final concentration of DMSO not higher than 0.1%. 2. Add DMSO to the control solution at the same concentration than that in the compound solution. 
Representative Results

Binding:
The in vitro assay with cell membranes is used to identify selective human GABA A α5β3γ2 receptor ligands binding at the BZD allosteric site of the γ2 containing receptors. Transiently transfected HEK293 cells expressing the human GABA A α5β3γ2, α1β3γ2, α2β3γ2, and α3β3γ2 receptors are used to prepare the membranes for this assay. The effect of the potential ligands is detected by measuring the scintillation of [ (Figure 8) . Figure 9 summarizes the profile of several reference compounds including that of the α5 selective GABA A receptor negative allosteric modulator, RO4938581 9 , which were generated using the binding assay.
Recordings in Xenopus oocytes:
The expression of GABA A receptors such as the α5β3γ2 heteromer yields robust currents in response to GABA exposure. Typical voltage clamp recordings obtained in an oocyte expressing the human α5β3γ2 in response to brief GABA pulses (30 s) ranging up to 300 µM are shown in Figure 6 . In this experiment, the different concentrations of GABA were disposed in the 96-well plate and the responses were evoked by moving the cell in a specific well. The GABA was thoroughly washed by returning the cell to the central perfusion chamber and applying a perfusion of control solution by activating the corresponding peristaltic pump. The program sequence used for the determination of the concentration activation curve is illustrated in Figure 6A . Conducted fully automatically, these data illustrate both the quality of the recordings that can be obtained in Xenopus oocytes and the high level of receptor expression obtained a few days after the mRNA injection. The experiments, conducted at different receptor combinations, yield a series of EC 50 s, which is the concentration of GABA necessary to activate half of the receptors. A plot of the EC 50 's values on a spider graph, such as illustrated in Figure 10 , provides a rapid comparison of the receptor properties and the influence of the subunit composition.
To examine the effect of a negative or positive allosteric modulator (NAM or PAM), it is necessary to compare the response evoked by an agonist (GABA) test pulse, first in the control and then in the presence of the modulator. An efficient experimental protocol to conduct such an experiment is illustrated in Figure 11 . The response of the cell to a reference concentration of GABA is first determined and the sequence is repeated by applying the same GABA concentration and then by a co-application of the GABA plus the modulator. A plot of the two superimposed responses reveals in this example a marked inhibition caused by the presence of the modulator. A quantification of the modulator effect is readily obtained by computing the ratio of the response evoked in the presence of the modulator versus the control and the results can be plotted in the form of a heat plot. The data shown in Figure 12 illustrate the heat plot corresponding to the recordings of three data sets obtained for 96 compounds.
Following the identification of compounds that are sufficiently active, it is often indispensable to assess if these molecules are active at other receptor combinations. In the case of the GABA A receptor, 19 genes encoding for different subunits have been identified, and it is known that a functional receptor can result from a multimeric assembly of different subunits (see Knoflach, Hernandez, and Bertrand 10 for a review). Although the multiple subunits and combinations yield a vast repertoire of receptor subtypes that might require a large number of counter screening to be performed, it is often possible to focus first on the most abundant subtype which, in the case of the GABA A receptors, is the α1β2γ2 composition. Experiments conducted head to head with the expression of, for example, α5β3γ2 and α1β2γ2 in the same batch of oocyte yield a good comparison of the respective effects of a given molecule. The typical results obtained in three cells for α5β3γ2 and α1β2γ2 are shown in Figure 13 , which illustrates the preferential positive modulation of one molecule at α5β3γ2.
The experimental protocol illustrated in Figure 11 is well suited for the characterization of a PAM activity. In this protocol, the compound that is tested is co-applied with the agonist at progressively increasing concentrations. To avoid the possible cumulative effects caused by multiple applications on the same cell, a new and naïve cell is measured for each data point. A measurement of the amplitude of the response recorded with the agonist alone and then during the compound application yields a ratio which quantifies the PAM or NAM effect. Typical results obtained at α1β2γ2 and α5β3γ2 for diazepam are shown in Figure 14 , revealing an apparent sensitivity of the α5β3γ2 that is approximately 10-fold higher at this receptor combination. These values are in good correlation with published data 11 . As it is thought that the benzodiazepine site is constituted by the interface between the γ2 and its adjacent α subunit 12, 13, 14 
Discussion
The development of novel compounds active at a ligand-gated ion channel such as the GABA A receptors requires the use of multiple approaches. Typically, the first step is often conducted using binding assays; however, such measurements are insufficient to characterize the physiological activity of the compound or its precise pharmacology. In particular, a compound that binds to a receptor may enhance or inhibit its function or even produce no functional effect (be silent) (i.e., bind to the receptor without modifying its function). Thus, a functional test is required for a full compound characterization.
Binding assays:
The main advantage of the binding assay is that it can be efficiently conducted on a large number of samples ranging up to several thousands and that it provides binding affinities for the active molecules. As described herein, the first step consists of establishing a method for the assessment of the desired receptor subtypes. Namely, while binding can be conducted on native receptors from fractions or entire brains, such a method will prevent the determination of the affinities at specific receptor subtypes. It is, therefore, necessary to use recombinant systems to screen molecules at the desired target. Nowadays, a transient or stable transfection of the desired receptor subunit cDNAs in cell lines offers an efficient and reliable method to express the receptor subtypes of interest (e.g., GABA A α5β3γ2). Traditional binding assays make use of radioligands, but nowadays techniques are available that avoid the inconvenience of handling radioactivity (e.g., quantitative fluorescence-based ligand-binding).
Functional expression in a host system:
To express genes in a host system, the coding sequence of interest must be inserted into a plasmid that contains the adequate promotors. Typically, for in vitro mRNA synthesis, the bacterial T7 or T6 promotors are used. For a cDNA expression, the transcription of the gene of interest must be regulated by a eukaryote promotor such as CMV (cytomegalovirus) or equivalent. Nowadays, several plasmids, including the two promotors (i.e., pUNIV, pCMV-6AC, psf-CMV/T7, pCI-neo, pcDNA), are available allowing either an in vitro synthesis of mRNA or a cDNA expression as shown in Figure 15 . An expression of the GABA A receptors can be faithfully obtained either in cell lines or in Xenopus oocytes. The main advantages of the latter are the lack of an endogenous receptor expression, the simplicity of manipulations, and the availability of an automated system for micro-injections and recordings. The procedures described in this protocol illustrate the efficiency of the automated system which allows the injection of 96 oocytes in about 7 min and requires no micromanipulation skills. Remembering that a single ovary from a Xenopus contains between 10,000-30,000 oocytes, it is clear that a large number of cell measurements can be conducted on a single preparation. Moreover, as an expression can be conducted using cDNA injections, the same plasmids containing the genes of interest that are developed for the binding experiments can be used for a functional characterization without the need for further molecular biology manipulations.
Given its large size and high surface expression, a single oocyte yields a number of receptors that is approximately equivalent to the confluent cells in a 35 mm Petri dish. However, an oocytes preparation and injection represents a fraction of the cost of a cell line, as the experiments do not require a specific culture medium and sterile manipulations. The activation of a single GABA A channel yields a few picoamperes (10 -12 ) and currents ranging up to tens of microampere (10 -6 ) are easily recorded in a single oocyte, which confirms the concomitant activity of several millions of receptors during a single response.
A first step in the characterization of ligand-gated ion channels is often the determination of the apparent affinity of the receptors. The experiments that need to be conducted consist of applying a series of brief agonist test pulses and plotting the amplitude of the evoked current or, in certain cases, the area under the curve (AUC) as a function of the logarithm of the agonist concentration. As it is easily feasible to microinject different plasmid concentrations and ratio in the same batch of oocytes, this system of expression is particularly appropriate for such
The results of the two-electrode voltage clamp obtained in Xenopus oocytes are often compared with recordings made using patch clamp electrodes. Whereas it would go beyond the scope of this work to go into a detailed comparison between these two systems, a few points can be examined. While a patch clamp in cells offers advantages for a biophysical characterization with a fast drug application, its requirements are more complex than those of the two-electrode recordings in Xenopus oocytes. A first and non-negligible difficulty is the expression of a given protein with the necessity of a cell culture, a transient or stable transfection, and the identification of the cells that are expressing the desired construct. In addition, it is indispensable to examine the possible contribution of the endogenous expression in the considered cell. Moreover, a patch clamp recording requires a skilled person to conduct the micromanipulation under a high-magnification microscope, while that person also needs to perform an adequate analysis during the experiment to assess, for example, the quality of the seal, the access resistance etc. In contrast, a two-electrode voltage clamp recording, especially one using an automated electrophysiological system, does not require any specific skills and can be conducted by laboratory technicians.
When acquiring an electrophysiological set-up, cost consideration is certainly an important factor that needs to be carefully analyzed. For example, while the cost of an automated system is relatively high, a closer comparison reveals that the installation of a complete electrophysiological rig includes buying equipment such as good micromanipulators, a binocular lens, an amplifier, a perfusion system, and an anti-vibration table, while also acquiring data and performing an analysis. A cost comparison between a two-electrode voltage clamp setup versus a patch clamp set-up reveals even further discrepancies. Moreover, the automated system offers the advantage of fully automated equipment and runs unattended day and night.
The pharmacological properties of a compound are determined by its mode of action at the receptor. For example, competitive inhibitors are molecules that can enter the same binding pocket, or orthosteric site, as the agonist itself causes a competition. Non-competitive inhibitors are compounds that inhibit the receptors by interacting at another site and, in the case of a ligand-gated ion channel, that can enter and block the ionic pore, for example. It would go beyond the scope of this work to examine the different mechanisms of interaction, but further information can be obtained from a pharmacological textbook and/or from other work such as Bertrand and Bertrand's 22 .
In the case of allosteric modulators, the compound binds at a site that is distinct from the orthosteric site, but the presence of the molecule modifies the energy barrier between the active and other states. Positive allosteric modulators (PAMs) are compounds that reduce the energy barrier from the resting to the active state and, therefore, enhance the effect of the agonist. To characterize possible PAM effects, it is, therefore, necessary to determine if an exposure to the compound enhances the response to the agonist and, if so, at which concentration. The experiments presented in Figure 11 and Figure 14 illustrate protocols that can be successfully used for the characterization of PAMs at the GABA A receptors.
In some cases, exposure to the PAM alone might be sufficient to activate the receptors. Such activity can be determined by a slight modification of the experimental protocol presented here. Namely, instead of using a co-application of the modulator during the exposure to the GABA, the protocol can be modified for the application of first the compound alone and then in the presence of the GABA. A characterization of the direct agonist activity will be made by the determination of the amplitude of the response evoked by the compound itself and compared to the GABAevoked current.
Experiments conducted in brain slices, such as illustrated in Figure 7 , are used to confirm the compound activity at native receptors in a definite inhibitory circuit before going further in animal models and along the pathway towards clinical trials. The relatively simple data recording and analysis protocol allows the ranking of multiple compounds by evaluating their differential modulatory effect on PS amplitude. Non-specific effects of compounds which are not related to the GABA system may also be detected (e.g., when changes in the PS shape are observed). Direct, GABAergic neurotransmission can be assessed in these cases by measuring the effects of the compounds on inhibitory postsynaptic currents (IPSCs) using the whole-cell patch clamp technique 8 .
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